MicroRNAs in malignant melanoma

Clinical Biochemistry

Volumn 46, Issue 10-11, 2013, Pages 909-917

  Völler, Daniel ^a   Ott, Corinna ^a   Bosserhoff, Anja ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Diagnostic; Melanoma; MiRNAs; Therapy

Indexed keywords

BIOLOGICAL MARKER; MICRORNA; TRANSCRIPTION FACTOR;

CANCER DIAGNOSIS; CANCER GROWTH; CANCER SURVIVAL; CARCINOGENIC ACTIVITY; GENE EXPRESSION; HUMAN; MELANOMA; PRIORITY JOURNAL; REVIEW;

ANIMALS; DISEASE-FREE SURVIVAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MELANOMA; MICRORNAS; NEOPLASM METASTASIS; NEOPLASM PROTEINS; PROTEIN BIOSYNTHESIS; RNA STABILITY; RNA, MESSENGER; RNA, NEOPLASM; SKIN NEOPLASMS; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84886304747     PISSN: 00099120     EISSN: 18732933     Source Type: Journal    
DOI: 10.1016/j.clinbiochem.2013.01.008     Document Type: Review

References (97)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Eheman C., Henley S.J., Ballard-Barbash R., Jacobs E.J., Schymura M.J., Noone A.M., et al. Annual Report to the Nation on the status of cancer, 1975-2008, featuring cancers associated with excess weight and lack of sufficient physical activity. Cancer 2012, 118:2338-2366.
3. Tsao H., Chin L., Garraway L.A., Fisher D.E. Melanoma: from mutations to medicine. Genes Dev 2012, 26:1131-1155.
4. Howell P.M., Liu S., Ren S., Behlen C., Fodstad O., Riker A.I. Epigenetics in human melanoma. Cancer Control 2009, 16:200-218.
5. Casaletto J.B., McClatchey A.I. Spatial regulation of receptor tyrosine kinases in development and cancer. Nat Rev Cancer 2012, 12:387-400.
6. Juliano R.L. Membrane receptors for extracellular matrix macromolecules: relationship to cell adhesion and tumor metastasis. Biochim Biophys Acta 1987, 907:261-278.
7. Ruoslahti E., Giancotti F.G. Integrins and tumor cell dissemination. Cancer Cells 1989, 1:119-126.
8. Albelda S.M., Mette S.A., Elder D.E., Stewart R., Damjanovich L., Herlyn M., et al. Integrin distribution in malignant melanoma: association of the beta 3 subunit with tumor progression. Cancer Res 1990, 50:6757-6764.
9. Van Belle P.A., Elenitsas R., Satyamoorthy K., Wolfe J.T., Guerry D., Schuchter L., et al. Progression-related expression of beta3 integrin in melanomas and nevi. Hum Pathol 1999, 30:562-567.
10. Muller D.W., Bosserhoff A.K. Integrin beta 3 expression is regulated by let-7a miRNA in malignant melanoma. Oncogene 2008, 27:6698-6706.
11. Kumar C.C. Integrin alpha v beta 3 as a therapeutic target for blocking tumor-induced angiogenesis. Curr Drug Targets 2003, 4:123-131.
12. Heinemann A., Zhao F., Pechlivanis S., Eberle J., Steinle A., Diederichs S., et al. Tumor suppressive microRNAs miR-34a/c control cancer cell expression of ULBP2, a stress-induced ligand of the natural killer cell receptor NKG2D. Cancer Res 2012, 72:460-471.
13. Migliore C., Petrelli A., Ghiso E., Corso S., Capparuccia L., Eramo A., et al. MicroRNAs impair MET-mediated invasive growth. Cancer Res 2008, 68:10128-10136.
14. Dong F., Lou D. MicroRNA-34b/c suppresses uveal melanoma cell proliferation and migration through multiple targets. Mol Vis 2012, 537-546.
15. Harris L.K., Crocker I.P., Baker P.N., Aplin J.D., Westwood M. IGF2 actions on trophoblast in human placenta are regulated by the insulin-like growth factor 2 receptor, which can function as both a signaling and clearance receptor. Biol Reprod 2011, 84:440-446.
16. Kaklamani V.G., Pasche B. Role of TGF-beta in cancer and the potential for therapy and prevention. Expert Rev Anticancer Ther 2004, 4:649-661.
17. Levy C., Khaled M., Iliopoulos D., Janas M.M., Schubert S., Pinner S., et al. Intronic miR-211 assumes the tumor suppressive function of its host gene in melanoma. Mol Cell 2010, 40:841-849.
18. Duncan L.M., Deeds J., Hunter J., Shao J., Holmgren L.M., Woolf E.A., Tepper R.I., Shyjan A.W. Down-regulation of the novel gene melastatin correlates with potential for melanoma metastasis. Cancer Res 1998, 58:1515-1520.
19. Mazar J., DeYoung K., Khaitan D., Meister E., Almodovar A., Goydos J., et al. The regulation of miRNA-211 expression and its role in melanoma cell invasiveness. PLoS One 2010, 5:e13779.
20. Alexeev V., Yoon K. Distinctive role of the cKit receptor tyrosine kinase signaling in mammalian melanocytes. J Invest Dermatol 2006, 126:1102-1110.
21. Igoucheva O., Alexeev V. MicroRNA-dependent regulation of cKit in cutaneous melanoma. Biochem Biophys Res Commun 2009, 379:790-794.
22. Hardy K.M., Kirschmann D.A., Seftor E.A., Margaryan N.V., Postovit L.M., Strizzi L., et al. Regulation of the embryonic morphogen Nodal by Notch4 facilitates manifestation of the aggressive melanoma phenotype. Cancer Res 2010, 70:10340-10350.
23. Costa F.F., Seftor E.A., Bischof J.M., Kirschmann D.A., Strizzi L., Arndt K., et al. Epigenetically reprogramming metastatic tumor cells with an embryonic microenvironment. Epigenomics 2009, 1:387-398.
24. Kundu S.T., Nallur S., Paranjape T., Boeke M., Weidhaas J.B., Slack F.J. KRAS alleles: the LCS6 3' UTR variant and KRAS coding sequence mutations in the NCI-60 panel. Cell Cycle 2012, 11:361-366.
25. Ascierto P.A., Kirkwood J.M. Adjuvant therapy of melanoma with interferon: lessons of the past decade. J Transl Med 2008, 6:62.
26. Yang C.H., Yue J., Pfeffer S.R., Handorf C.R., Pfeffer L.M. MicroRNA miR-21 regulates the metastatic behavior of B16 melanoma cells. J Biol Chem 2011, 286:39172-39178.
27. Satzger I., Mattern A., Kuettler U., Weinspach D., Niebuhr M., Kapp A., et al. MicroRNA-21 is upregulated in malignant melanoma and influences apoptosis of melanocytic cells. Exp Dermatol 2012, 21:509-514.
28. Ciuffreda L., Di Sanza C., Cesta I.U., Eramo A., Desideri M., Biagioni F., et al. The mitogen-activated protein kinase (MAPK) cascade controls phosphatase and tensin homolog (PTEN) expression through multiple mechanisms. J Mol Med (Berl) 2012, 90:667-679.
29. Madhunapantula S.V., Robertson G.P. The PTEN-AKT3 signaling cascade as a therapeutic target in melanoma. Pigment Cell Melanoma Res 2009, 22:400-419.
30. Karreth F.A., Tay Y., Perna D., Ala U., Tan S.M., Rust A.G., et al. In vivo identification of tumor- suppressive PTEN ceRNAs in an oncogenic BRAF-induced mouse model of melanoma. Cell 2011, 147:382-395.
31. Nguyen T., Kuo C., Nicholl M.B., Sim M.S., Turner R.R., Morton D.L., et al. Downregulation of microRNA-29c is associated with hypermethylation of tumor-related genes and disease outcome in cutaneous melanoma. Epigenetics 2011, 6:388-394.
32. G.P. Pfeifer, R. Dammann, Methylation of the tumor suppressor gene RASSF1A in human tumors, Biochem; 2005 (Mosc).
33. Chen J., Feilotter H.E., Pare G.C., Zhang X., Pemberton J.G., Garady C., et al. MicroRNA-193b represses cell proliferation and regulates cyclin D1 in melanoma. Am J Pathol 2010, 176:2520-2529.
34. Schultz J., Lorenz P., Gross G., Ibrahim S., Kunz M. MicroRNA let-7b targets important cell cycle molecules in malignant melanoma cells and interferes with anchorage-independent growth. Cell Res 2008, 18:549-557.
35. Das S.K., Sokhi U.K., Bhutia S.K., Azab B., Su Z.Z., Sarkar D., et al. Human polynucleotide phosphorylase selectively and preferentially degrades microRNA-221 in human melanoma cells. Proc Natl Acad Sci U S A 2010, 107:11948-11953.
36. Xu K., Moghal N., Egan S.E. Notch signaling in lung development and disease. Adv Exp Med Biol 2012, 727:89-98.
37. Gozdecka M., Breitwieser W. The roles of ATF2 (activating transcription factor 2) in tumorigenesis. Biochem Soc Trans 2012, 40:230-234.
38. Poser I., Bosserhoff A.K. Transcription factors involved in development and progression of malignant melanoma. Histol Histopathol 2004, 19:173-188.
39. Poser I., Dominguez D., de Herreros A.G., Varnai A., Buettner R., Bosserhoff A.K. Loss of E-cadherin expression in melanoma cells involves up-regulation of the transcriptional repressor Snail. J Biol Chem 2001, 276:24661-24666.
40. Sou P.W., Delic N.C., Halliday G.M., Lyons J.G. Snail transcription factors in keratinocytes: enough to make your skin crawl. Int J Biochem Cell Biol 2010, 42:1940-1944.
41. Liu S., Kumar S.M., Lu H., Liu A., Yang R., Pushparajan A., et al. MicroRNA-9 up-regulates E-cadherin through inhibition of NF-kappaB1-Snail1 pathway in melanoma. J Pathol 2012, 226:61-72.
42. Massoumi R., Kuphal S., Hellerbrand C., Haas B., Wild P., Spruss T., Pfeifer A., Fassler R., Bosserhoff A.K. Down-regulation of CYLD expression by Snail promotes tumor progression in malignant melanoma. J Exp Med 2009, 206:221-232.
43. Lodygin D., Tarasov V., Epanchintsev A., Berking C., Knyazeva T., Korner H., et al. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 2008, 7:2591-2600.
44. Yamazaki H., Chijiwa T., Inoue Y., Abe Y., Saegusa M., Nakamura M. Overexpression of the miR-34 family suppresses invasive growth of malignant melanoma with the wild-type p53 gene. Exp Ther Med 2012, 3:793-796.
45. Garraway L.A., Widlund H.R., Rubin M.A., Getz G., Berger A.J., Ramaswamy S., et al. Integrative genomic analyses identify MITF as a lineage survival oncogene amplified in malignant melanoma. Nature 2005, 436:117-122.
46. Hoek K.S., Goding C.R. Cancer stem cells versus phenotype-switching in melanoma. Pigment Cell Melanoma Res 2010, 23:746-759.
47. Haflidadottir B.S., Bergsteinsdottir K., Praetorius C., Steingrimsson E. miR-148 regulates Mitf in melanoma cells. PLoS One 2010, 5:e11574.
48. Segura M.F., Hanniford D., Menendez S., Reavie L., Zou X., Alvarez-Diaz S., Zakrzewski J., Blochin E., Rose A., Bogunovic D., Polsky D., Wei J., Lee P., Belitskaya-Levy I., Bhardwaj N., Osman I., Hernando E. Aberrant miR-182 expression promotes melanoma metastasis by repressing FOXO3 and microphthalmia-associated transcription factor. Proc Natl Acad Sci U S A 2009, 106:1814-1819.
49. Bemis L.T., Chen R., Amato C.M., Classen E.H., Robinson S.E., Coffey D.G., et al. MicroRNA-137 targets microphthalmia-associated transcription factor in melanoma cell lines. Cancer Res 2008, 68:1362-1368.
50. Deng Y., Deng H., Bi F., Liu J., Bemis L.T., Norris D., et al. MicroRNA-137 targets carboxyl-terminal binding protein 1 in melanoma cell lines. Int J Biol Sci 2011, 7:133-137.
51. Levati L., Pagani E., Romani S., Castiglia D., Piccinni E., Covaciu C., Caporaso P., Bondanza S., Antonetti F.R., Bonmassar E., Martelli F., Alvino E., D'Atri S. MicroRNA-155 targets the SKI gene in human melanoma cell lines. Pigment Cell Melanoma Res 2011, 24:538-550.
52. Chen D., Xu W., Bales E., Colmenares C., Conacci-Sorrell M., Ishii S., Stavnezer E., Campisi J., Fisher D.E., Ben Ze'ev A., Medrano E.E. SKI activates Wnt/beta-catenin signaling in human melanoma. Cancer Res 2003, 63:6626-6634.
53. Cillo C., Cantile M., Mortarini R., Barba P., Parmiani G., Anichini A. Differential patterns of HOX gene expression are associated with specific integrin and ICAM profiles in clonal populations isolated from a single human melanoma metastasis. Int J Cancer 1996, 66:692-697.
54. Mueller D.W., Bosserhoff A.K. MicroRNA miR-196a controls melanoma-associated genes by regulating HOX-C8 expression. Int J Cancer 2011, 129:1064-1074.
55. Braig S., Mueller D.W., Rothhammer T., Bosserhoff A.K. MicroRNA miR-196a is a central regulator of HOX-B7 and BMP4 expression in malignant melanoma. Cell Mol Life Sci 2010, 67:3535-3548.
56. Noguchi S., Mori T., Otsuka Y., Yamada N., Yasui Y., Iwasaki J., et al. Anti-oncogenic microRNA-203 induces senescence by targeting E2F3 protein in human melanoma cells. J Biol Chem 2012, 287:11769-11777.
57. Dar A.A., Majid S., de Semir D., Nosrati M., Bezrookove V., Kashani-Sabet M. MiRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein. J Biol Chem 2011, 286:16606-16614.
58. Berlin I., Denat L., Steunou A.L., Puig I., Champeval D., Colombo S., et al. Phosphorylation of BRN2 modulates its interaction with the Pax3 promoter to control melanocyte migration and proliferation. Mol Cell Biol 2012, 32:1237-1247.
59. Boyle G.M., Woods S.L., Bonazzi V.F., Stark M.S., Hacker E., Aoude L.G., Dutton-Regester K., Cook A.L., Sturm R.A., Hayward N.K. Melanoma cell invasiveness is regulated by miR-211 suppression of the BRN2 transcription factor. Pigment Cell Melanoma Res 2011, 24:525-537.
60. Penna E., Orso F., Cimino D., Tenaglia E., Lembo A., Quaglino E., et al. MicroRNA-214 contributes to melanoma tumour progression through suppression of TFAP2C. EMBO J 2011, 30:1990-2007.
61. Kitago M., Martinez S.R., Nakamura T., Sim M.S., Hoon D.S. Regulation of RUNX3 tumor suppressor gene expression in cutaneous melanoma. Clin Cancer Res 2009, 15:2988-2994.
62. Mazar J., DeBlasio D., Govindarajan S.S., Zhang S., Perera R.J. Epigenetic regulation of microRNA-375 and its role in melanoma development in humans. FEBS Lett 2011, 585:2467-2476.
63. Mazar J., Khaitan D., DeBlasio D., Zhong C., Govindarajan S.S., Kopanathi S., et al. Epigenetic regulation of microRNA genes and the role of miR-34b in cell invasion and motility in human melanoma. PLoS One 2011, 6:e24922.
64. Yoo B.K., Santhekadur P.K., Gredler R., Chen D., Emdad L., Bhutia S., Pannell L., Fisher P.B., Sarkar D. Increased RNA-induced silencing complex (RISC) activity contributes to hepatocellular carcinoma. Hepatology 2011, 53:1538-1548.
65. Gregory R.I., Yan K.P., Amuthan G., Chendrimada T., Doratotaj B., Cooch N., Shiekhattar R. The microprocessor complex mediates the genesis of microRNAs. Nature 2004, 432:235-240.
66. Grund S.E., Polycarpou-Schwarz M., Luo C., Eichmuller S.B., Diederichs S. Rare Drosha splice variants are deficient in microRNA processing but do not affect general microRNA expression in cancer cells. Neoplasia 2012, 14:238-248.
67. Muralidhar B., Goldstein L.D., Ng G., Winder D.M., Palmer R.D., Gooding E.L., Barbosa-Morais N.L., Mukherjee G., Thorne N.P., Roberts I., Pett M.R., Coleman N. Global microRNA profiles in cervical squamous cell carcinoma depend on Drosha expression levels. J Pathol 2007, 212:368-377.
68. Yi R., Pasolli H.A., Landthaler M., Hafner M., Ojo T., Sheridan R., et al. DGCR8-dependent microRNA biogenesis is essential for skin development. Proc Natl Acad Sci U S A 2009, 106:498-502.
69. Wang Y., Medvid R., Melton C., Jaenisch R., Blelloch R. DGCR8 is essential for microRNA biogenesis and silencing of embryonic stem cell self-renewal. Nat Genet 2007, 39:380-385.
70. Han J., Pedersen J.S., Kwon S.C., Belair C.D., Kim Y.K., Yeom K.H., et al. Posttranscriptional crossregulation between Drosha and DGCR8. Cell 2009, 136:75-84.
71. Yi R., Qin Y., Macara I.G., Cullen B.R. Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. Genes Dev 2003, 17:3011-3016.
72. Melo S.A., Moutinho C., Ropero S., Calin G.A., Rossi S., Spizzo R., et al. A genetic defect in exportin-5 traps precursor microRNAs in the nucleus of cancer cells. Cancer Cell 2010, 18:303-315.
73. Lee Y.S., Nakahara K., Pham J.W., Kim K., He Z., Sontheimer E.J., et al. Distinct roles for Drosophila Dicer-1 and Dicer-2 in the siRNA/miRNA silencing pathways. Cell 2004, 117:69-81.
74. Sand M., Gambichler T., Sand D., Altmeyer P., Stuecker M., Bechara F.G. Immunohistochemical expression patterns of the microRNA-processing enzyme Dicer in cutaneous malignant melanomas, benign melanocytic nevi and dysplastic melanocytic nevi. Eur J Dermatol 2011, 21:18-21.
75. Levy C., Khaled M., Robinson K.C., Veguilla R.A., Chen P.H., Yokoyama S., et al. Lineage-specific transcriptional regulation of DICER by MITF in melanocytes. Cell 2010, 141:994-1005.
76. Bernstein E., Kim S.Y., Carmell M.A., Murchison E.P., Alcorn H., Li M.Z., Mills A.A., Elledge S.J., Anderson K.V., Hannon G.J. Dicer is essential for mouse development. Nat Genet 2003, 35:215-217.
77. Ma Z., Swede H., Cassarino D., Fleming E., Fire A., Dadras S.S. Up-regulated Dicer expression in patients with cutaneous melanoma. PLoS One 2011, 6:e20494.
78. Zhang L., Huang J., Yang N., Greshock J., Megraw M.S., Giannakakis A., et al. MicroRNAs exhibit high frequency genomic alterations in human cancer. Proc Natl Acad Sci U S A 2006, 103:9136-9141.
79. Bouillet P., Purton J.F., Godfrey D.I., Zhang L.C., Coultas L., Puthalakath H., et al. BH3-only Bcl-2 family member Bim is required for apoptosis of autoreactive thymocytes. Nature 2002, 415:922-926.
80. S.M. Jafarnejad, G.S. Ardekani, M. Ghaffari, M. Martinka, G. Li. Sox4-mediated Dicer expression is critical for suppression of melanoma cell invasion. Oncogene in press.
81. Schwarz D.S., Hutvagner G., Du T., Xu Z., Aronin N., Zamore P.D. Asymmetry in the assembly of the RNAi enzyme complex. Cell 2003, 115:199-208.
82. Meister G., Tuschl T. Mechanisms of gene silencing by double-stranded RNA. Nature 2004, 431:343-349.
83. Sand M., Skrygan M., Georgas D., Sand D., Gambichler T., Altmeyer P., et al. The miRNA machinery in primary cutaneous malignant melanoma, cutaneous malignant melanoma metastases and benign melanocytic nevi. Cell Tissue Res 2012, 350(1):119-126.
84. Rubin K.M., Lawrence D.P. Your patient with melanoma: staging, prognosis, and treatment. Oncology (Williston Park) 2009, 23:13-21.
85. Weber J.A., Baxter D.H., Zhang S., Huang D.Y., Huang K.H., Lee M.J., et al. The microRNA spectrum in 12 body fluids. Clin Chem 2010, 56:1733-1741.
86. Mitchell P.S., Parkin R.K., Kroh E.M., Fritz B.R., Wyman S.K., Pogosova-Agadjanyan E.L., et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A 2008, 105:10513-10518.
87. Bartels C.L., Tsongalis G.J. MicroRNAs: novel biomarkers for human cancer. Clin Chem 2009, 55:623-631.
88. Cortez M.A., Bueso-Ramos C., Ferdin J., Lopez-Berestein G., Sood A.K., Calin G.A. MicroRNAs in body fluids-the mix of hormones and biomarkers. Nat Rev Clin Oncol 2011, 8:467-477.
89. Brase J.C., Wuttig D., Kuner R., Sultmann H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 2010, 9:306-309. 10.1186/1476-4598-9-306.
90. Leidinger P., Keller A., Borries A., Reichrath J., Rass K., Jager S.U., et al. High-throughput miRNA profiling of human melanoma blood samples. BMC Cancer 2010, 10:262.
91. Kanemaru H., Fukushima S., Yamashita J., Honda N., Oyama R., Kakimoto A., Masuguchi S., Ishihara T., Inoue Y., Jinnin M., Ihn H. The circulating microRNA-221 level in patients with malignant melanoma as a new tumor marker. J Dermatol Sci 2011, 61:187-193.
92. Satzger I., Mattern A., Kuettler U., Weinspach D., Voelker B., Kapp A., Gutzmer R. MicroRNA-15b represents an independent prognostic parameter and is correlated with tumor cell proliferation and apoptosis in malignant melanoma. Int J Cancer 2010, 126:2553-2562.
93. Caramuta S., Egyhazi S., Rodolfo M., Witten D., Hansson J., Larsson C., Lui W.O. MicroRNA expression profiles associated with mutational status and survival in malignant melanoma. J Invest Dermatol 2010, 130:2062-2070.
94. Segura M.F., Belitskaya-Levy I., Rose A.E., Zakrzewski J., Gaziel A., Hanniford D., et al. Melanoma MicroRNA signature predicts post-recurrence survival. Clin Cancer Res 2010, 16:1577-1586.
95. Bader A.G., Brown D., Winkler M. The promise of microRNA replacement therapy. Cancer Res 2010, 70:7027-7030.
96. Felicetti F., Errico M.C., Bottero L., Segnalini P., Stoppacciaro A., Biffoni M., et al. The promyelocytic leukemia zinc finger-microRNA-221/-222 pathway controls melanoma progression through multiple oncogenic mechanisms. Cancer Res 2008, 68:2745-2754.
97. Zhou Q., Zhang X.S. Adjuvant interferon therapy for malignant melanoma: the debate. Chin J Cancer 2010, 29:907-913.